Company
Representative Message
Masanori Nishiwaki,
Chairman of the Board
Aiming to realize innovation on manufacturing technology for APIs and intermediates, the companies with specialized technologies and functions have come together to establish Pharmira Co., Ltd. to provide contract development and manufacturing services. The environment surrounding APIs and intermediates is undergoing major changes. Especially against the threat of infectious diseases, it is an urgent issue to further accelerate pharmaceutical development and build a stable supply network for APIs. By introducing continuous manufacturing technology as an innovative new technology in response to these environmental changes, it is expected
that the time required for development of manufacturing methods in the pharmaceutical development stage will be shortened. Continuous manufacturing technology is also expected to improve the efficiency of commercial production by conserving manpower and space and to
enable advanced quality assurance for high-quality pharmaceutical products. In order to meet diverse customer needs, we provide pharmaceutical development and manufacturing services using both continuous manufacturing technology and the already well-established batch manufacturing technology. Specifically, we apply continuous manufacturing to the processes that will have significant benefits by switching to continuous manufacturing from the development stage to accelerate the development of pharmaceutical products while ensuring high quality and process safety. We continue to challenge for the future of API’s manufacturing technology with our customers in order to contribute for advancement and improvement of global medical environment and sustainable social growth. We sincerely request your continued support and encouragement.
Derivation of Company’s Name
Pharmira consists of two words, pharmaceutical and MIRAI which means “Future” in Japanese consistent with our mission to break ground future for pharmaceutical.
Corporate Profile
Company Name | Pharmira Co., Ltd. |
Established | November 25, 2021 |
Representative | Masanori Nishiwaki, Chairman of the Board |
Number of Employees | 35 people |
Address | 1-3, Kuise Terajima 2-chome, Amagasaki, Hyogo 660-0813, Japan |
Shareholders | Shionogi Pharma Co., Ltd., Chiyoda Corporation, Taisei Corporation, Fujimoto Chemicals Co., Ltd., Takenaka Corporation, Yokogawa Electric Corporation, Nagase & Co., Ltd. |
Business Activities | Manufacturing and analytical testing of APIs and intermediates for medicinal drugs and investigational drugs. |
Access to Pharmira
From Adjacent Stations
-Kuise Station, Hanshin Main Line: a twelve-minute walk.
-Amagasaki Station, JR Tokai Main Line: five minutes by car